Get to know our Immune profiling services

Our highly trained team of immunologists leverage knowledge of immune response, disease understanding and therapeutic expertise to provide a diverse set of tools for immune monitoring and profiling. We have multiple universal assays developed that will give you more answers for the same sample volume.

Measurable Residual Disease Detection and Monitoring

Measurable residual disease (MRD, also referred to as minimal residual disease) refers to the small number of cancer cells that remain in the body after treatment, even when the patient is in remission. Multiple studies demonstrated lower MRD correlates with superior survival, thus, sensitive, and reliable detection methods can enable development of more effective treatments. MRD can be detected by using sensitive techniques such as flow cytometry, next-generation sequencing, or digital PCR, which can measure one cancer cell among millions of normal cells. Detecting and monitoring MRD not only provides important information about the effectiveness of treatment but also predicts risk of relapse, which could indicate the need for alternative therapy.

Navigate BioPharma Services offers a variety of MRD testing solutions for clinical trials to sensitively and reliably monitor tumor burden in patients and assist with understanding the efficacy of investigational treatments. These powerful tools can ultimately be used to support real world efficacy and drug reimbursement for specialized therapies, such as CAR-T.

There are special benefits to incorporating flow cytometry-based MRD methods in clinical trials of blood cancer patients, including the phenotype of both the original tumor cell and escape variants, density or loss of target antigens and the coverage for a diverse group of blood cancers.  

Utility of MRD Test Methods 

• Assess clinical response and prognosis 
• Strengthen clinical response interpretation e.g., MRD negativity in Complete Responders
• Guide the optimization of treatment strategies e.g., need for a stem cell transplant 
• Monitor the patient's disease status during follow-up and detect any signs of relapse before clinical presentation

Table 1: Available MRD Flow Test Panels

Immunogenicity assays

Immunogenicity assays are complex and integral to biologic treatment development. We have the solutions you need for immunogenicity testing from pre-clinical through clinical development.